Very simple response. The fact is, there is unmet market need. The only treatment which was the most recently approved drug fails in phase 3 trials so we are next in line. You just have to look at the number of patients diagnosed annually and the potential pricing to make up your own minds.
No advice.
Ann: Media clarification, page-2
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $90.85M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 24.0¢ | 20.5¢ | $392.9K | 1.807M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 189100 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 52700 | 3 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
23.0¢ |
Change
0.010 ( 3.37 %) |
||||
| Open | High | Low | Volume | ||
| 21.0¢ | 24.0¢ | 20.5¢ | 734616 | ||
| Last updated 15.58pm 01/05/2024 ? | |||||
| PAA (ASX) Chart |